- Conditions
- CDD
- Interventions
- Fenfluramine Hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- 15q Duplication Syndrome, CDKL5 Deficiency Disease
- Interventions
- Soticlestat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 3 more
- Conditions
- Solid Tumor
- Interventions
- Decitabine, Cedazuridine
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Baltimore, Maryland
- Conditions
- Myelodysplastic Syndrome, MDS
- Interventions
- ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 9 more
- Conditions
- CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
- Interventions
- Fenfluramine, Placebo
- Drug
- Lead sponsor
- Zogenix, Inc.
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
- Interventions
- No intervention; observational
- Other
- Lead sponsor
- Loulou Foundation
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 6 more
- Conditions
- CDKL5, CDKL5 Deficiency Disorder, CDD
- Interventions
- No intervention.
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Month to 100 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 5 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas
- Interventions
- Decitabine (DAC), Tetrahydrouridine (THU), Pembrolizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Myeloid Leukemia
- Interventions
- ASTX660, ASTX727
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- San Francisco, California • New Haven, Connecticut • Miami, Florida + 11 more
- Conditions
- CDKL5 Deficiency Disorder
- Interventions
- ganaxolone, Placebo
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
- Conditions
- CDKL5 Deficiency Disorder (CDD)
- Interventions
- Survey Instrument
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania